AVLN

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

Avalyn Announces ERS 2026 Posters on IPF Trials and AP01 Modeling

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Avalyn Pharma announced two ERS 2026 posters in Barcelona, Sept 5–9: one on IPF trial participation perspectives and another on AP01 nebulized pirfenidone modeling. The events underscore ongoing AP01, AP02, and AP03 programs and global Phase 2 efforts (MIST and AURA). Positive data signals could support longer-term valuation but near-term impact remains data-dependent.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Avalyn to present two ERS 2026 posters on IPF trials.</li><li>Poster 246 covers real-world IPF trial participation factors.</li><li>In silico AP01 nebulized pirfenidone modeling predicts lung distribution.</li><li>AVLN&#039;s AP01/AP02/AP03 pipeline updates highlighted at ERS.</li><li>Posters available online; congress in Barcelona Sept 5–9, 2026.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Avalyn Pharma Inc. (AVLN)</strong>: Announces ERS 2026 posters; pipeline AP01/AP02/AP03 progress; potential data catalysts.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News: Signals ongoing pipeline progress and scientific communication around AVLN&#039;s inhaled antifibrotic programs, which could influence sentiment and valuation.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>ERS 2026 posters may lift sentiment on AVLN&#039;s inhaled therapy platform.</li><li>AP01 in silico modeling outcomes could influence perception of lung-targeted delivery.</li><li>No immediate Phase 2/3 readouts; price impact is sentiment-driven.</li><li>Positive framing at ERS could support modest share-price gains if data align.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Event: ERS International Congress 2026 in Barcelona, Sept 5–9.</li><li>Poster 246: Understanding patient perspectives on IPF trial participation; presenting author Brittany Davis, Ph.D.</li><li>Session time: Sept 7, 8:00–9:30 GMT; Poster PA3014.</li><li>Poster 378: In silico modeling of AP01; Session PS-9; Poster PA4377.</li><li>AP01 in MIST Phase 2b; AP02 in AURA Phase 2; AP03 in development.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral to mildly bullish near term; watch ERS posters for AP01 signals over 1–3 months.</p>
  </section>
</section>


<article><p>BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) — Avalyn Pharma Inc. (NASDAQ: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced two upcoming poster presentations at the European Respiratory Society (ERS) International Congress 2026, being held September 5-9, 2026, in Barcelona, Spain.</p>

<section aria-labelledby="ers-poster-details">
  <h2 id="ers-poster-details">ERS 2026 Poster Presentation Details</h2>

  <ul>
    <li>
      <p><strong>Poster 1</strong>: <em>Understanding patient perspectives on IPF clinical trial participation: Preferences, motivations, and comfort with study design</em></p>
      <ul>
        <li><strong>Poster Session</strong>: #246: Real-world studies: acute exacerbations and pulmonary fibrosis treatment</li>
        <li><strong>Presenting Author</strong>: Brittany Davis, Ph.D., Avalyn Pharma</li>
        <li><strong>Location</strong>: PS-34, Poster #: PA3014</li>
        <li><strong>Date and Time</strong>: <strong>September 7, 2026</strong>, between <strong>8:00 a.m. – 9:30 a.m. GMT</strong> (<strong>4:00 a.m. – 5:30 a.m. EDT</strong>)</li>
      </ul>
    </li>

    <li>
      <p><strong>Poster 2</strong>: <em>In silico modeling of a novel nebulized pirfenidone formulation (AP01) predicts aerosol distribution throughout the lung</em></p>
      <ul>
        <li><strong>Poster Session</strong>: #378: Molecular mechanisms and clinical strategies in interstitial lung diseases</li>
        <li><strong>Author</strong>: Michelle Palacios, Ph.D., DABT, Avalyn Pharma</li>
        <li><strong>Session</strong>: PS-9, Poster #: PA4377</li>
        <li><strong>Date and Time</strong>: <strong>September 7, 2026</strong>, between <strong>12:30 p.m. – 2:00 p.m. GMT</strong> (<strong>8:30 a.m. – 10:00 a.m. EDT</strong>)</li>
      </ul>
    </li>
  </ul>

  <p>See the ERS <a href="https://www.globenewswire.com/Tracker?data=T9EFVBiUCx379RgO3LXp3CaC9_8h6JHINxTHZEed1uJDbtpK0iBE40xNPvvxUsvCKNhywxqRys9RuLtxpX0PzRY8cx0GrKcSV-uWw4mP_QW91tQjDU-jMt84avvuHc5H" rel="nofollow" target="_blank">online program</a> for more details. The presentations will also be accessible on the company’s <a href="https://www.globenewswire.com/Tracker?data=VxTn8Jd7miHBAr0K4GIKUdjLk5n2LDzh-JzgZcGFegU4qX_ggRDZ_-UXmcXN3uAFYS8B96uokRjTfxCL_9Rjci0cZjCBYlbH3jS0VL6fiN0GkheINyEEsKtO4ukAs9ve" rel="nofollow" target="_blank">website</a>.</p>
</section>

<section aria-labelledby="about-avalyn" id="about-avalyn">
  <h2>About Avalyn Pharma</h2>
  <p>Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=3y98aI1SvWP3rUtKgzNpZsq_deoWxFK9Ht9vTeaSALLl2Yl7os3mWx7uNpbvHzbwmlH37STkoVBeXvRl5TKAkuoG1raKTUxcpPIKPzLutXQLEeyxR0ZsnuNOQK87_xeYDSIlDMuFnc_r9IGR7-LbtFu5kZXMF_bqK7EDEVz1ZQooUm4N8e9JKlo-gL4VZeSYVrqNi2u1w2TfvAEOn6eYxJZOrLHiNAanGQDYG1iwpy46UHIadQ4VndRDEltWBvpT6siCy6jqxf7AWJp-P5-4kw==" rel="nofollow" target="_blank"><u>avalynpharma.com</u></a> and follow the company on <a href="https://www.globenewswire.com/Tracker?data=c-KRTC-YTbhsEkcuQwZe_kCj2FoZXEQbumfnXDJvHe8O0ZvNYWXVWOq1FOxzeEuQ-6i-syUPldL9u2XvGrrNBIz1q1-ri1pXMgSdqOCuakJEpCNLmZKjKzs3nd2h4zuhA9bnfh25ACCWeKh0zvLoCPUZzjyskVwusoxVABKYgQKiz3Iv_IOB5BRQbBxstjDRM58Qa5FCECnR_6WMKe5sPOio4OAUhVIgQpgVJbEQ9xAiysvCq-2oLf5AKendwAVISt_SNBH-aWeZVHIVJq7IQw==" rel="nofollow" target="_blank"><u>LinkedIn</u></a>.</p>

  <p>Avalyn’s AP01 is an optimized inhaled formulation of pirfenidone evaluated in MIST (Phase 2b), AP02 is an optimized inhaled formulation of nintedanib evaluated in AURA (Phase 2), and AP03 is an inhaled fixed-dose combination of pirfenidone and nintedanib. These programs illustrate Avalyn’s strategy to deliver antifibrotic therapies directly to the lungs, aiming to preserve lung function while improving tolerability. For more information, please visit avalynpharma.com.</p>
</section>

<section aria-labelledby="contacts" id="contacts">
  <h2>Investor and Media Contacts</h2>
  <ul>
    <li><strong>Investor Contact:</strong> Cassie Saitow, Avalyn Pharma Inc., Sr. Director, IR and Corporate Communications</li>
    <li><strong>Investor Email:</strong> ir@avalynpharma.com</li>
    <li><strong>Media Contact:</strong> Precision AQ</li>
    <li><strong>Media Email:</strong> avalyn@precisionaq.com</li>
  </ul>
</section></article>

Avalyn Pharma announced two ERS 2026 posters in Barcelona, Sept 5–9: one on IPF trial participation perspectives and another on AP01 nebulized pirfenidone modeling. The events underscore ongoing AP01, AP02, and AP03 programs and global Phase 2 efforts (MIST and AURA). Positive data signals could support longer-term valuation but near-term impact remains data-dependent.

News insight

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

AI summary

Sentiment rationale

Key facts

Industry News